Wednesday, August 26, 2015 4:31:11 PM
You know, I buy above a called-bottom too...but just a little.
1.06? Who are you trying to kidd? A decent chunk @ 1.19 will be a good catch. Your targets are way beyond the 'bands of reality'.
InforichIH: Thank you. My bad for not using the correct figure. I have made the same comment and concur. That was my reasoning for posting the snappy answer, but I was too focused on the poster in question to respond correctly. Epic fail!
Oh! I just lost the beer I got from WW!!!
"The recent clinical disappointments for Alzheimer's have focused on removing abeta plaques in the brain, which may be too simplistic and too far downstream an approach to be effective. Instead, we took a different approach: Target the potential cause of the disease, further upstream. Our view is that Alzheimer's could be caused by chronic cell stress, which in turn, could trigger protein misfolding in the brain. Anavex's drug candidates are not targeting the downstream protein aggregations itself. Rather, the drug candidates take a farther upstream neuroprotective strategy that may help the brain to either prevent or remove the protein misfoldoing in the distressed cells."
http://lifescienceleadermag.epubxp.com/i/547536-aug-2015/49
Good day to get into the little redhead...
§AVXL
1.06? Who are you trying to kidd? A decent chunk @ 1.19 will be a good catch. Your targets are way beyond the 'bands of reality'.
InforichIH: Thank you. My bad for not using the correct figure. I have made the same comment and concur. That was my reasoning for posting the snappy answer, but I was too focused on the poster in question to respond correctly. Epic fail!
What are you doing when the price is going up? Building a robot in your basement?
"The recent clinical disappointments for Alzheimer's have focused on removing abeta plaques in the brain, which may be too simplistic and too far downstream an approach to be effective. Instead, we took a different approach: Target the potential cause of the disease, further upstream. Our view is that Alzheimer's could be caused by chronic cell stress, which in turn, could trigger protein misfolding in the brain. Anavex's drug candidates are not targeting the downstream protein aggregations itself. Rather, the drug candidates take a farther upstream neuroprotective strategy that may help the brain to either prevent or remove the protein misfoldoing in the distressed cells."
http://lifescienceleadermag.epubxp.com/i/547536-aug-2015/49
Good day to get into the little redhead...
§AVXL
Recent AVXL News
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
- Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference • GlobeNewswire Inc. • 11/26/2025 12:30:00 PM
